Developing several pre-clinical programs for smart delivery of tumour disrupting drugs for multiple solid cancers. Interested in collaborating/partnering for clinical development. With its stealth virus platform technology, Trocept, Accession Therapeutics is focused on treating some of the most intractable and widespread forms of cancer. Led by immuno-oncology pioneer Bent Jakobsen, PhD FMedSci, the company is accelerating a pipeline of highly differentiated products towards the clinic. Trocept has generated exceptionally encouraging preclinical data. Accession Therapeutics’ first drug candidate is expected to be IND stage by late 2023, followed by a pipeline of candidates engineered to make a step-change in cancer treatment.